Submitted by Anonymous (not verified) on 8 September 2026 - 16:20
Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 35, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 35, Status: Authorised